Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial
Abstract
INTRODUCTION: PEACE-1 is a 2×2 factorial phase III trial evaluating the impact of abiraterone-prednisone and prostate radiotherapy in patients with de novo metastatic castration-sensitive prostate cancer (mCSPC). Abiraterone-prednisone significantly improved overall survival (OS) (hazard ratio (HR)= 0.82 [95 %CI, 0.69-0.98]). In the control arm, men often received an androgen receptor pathway inhibitor (ARPI) - either abiraterone-prednisone or enzalutamide - after progression to castration-resistant disease. The use of active drug beyond progression may improve post-progression survival and thereby attenuate the estimated benefit of early use of this drug in intention-to-treat analyses.
METHODS: This post-hoc analysis applied three statistical methods to estimate an adjusted HR accounting for abiraterone-prednisone use beyond progression: Two-Stage Estimation (TSE), Inverse Probability of Censoring Weighting (IPCW) and Rank-Preserving Structural Failure Time Models (RPSFTM).
RESULTS: Among 589 patients randomised to the control arm, 183 received abiraterone-prednisone after disease progression. Compared with patients who did not, these men had higher PSA at diagnosis, higher tumour burden, more bone metastases, and were more likely to have received docetaxel for mCSPC. Experiencing biochemical progression was found to be a risk factor for 2nd line abiraterone use. The HR for OS adjusted by RPSFTM, IPCW, and TSE were 0.79 [0.64-0.98], 0.75 [0.62-0.92], and 0.82 [0.67-0.98],…
How strong is the evidence?
Evidence Hub reads this as a secondary / pooled analysis, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 589 participants or records.
Read the paper
Related studies
- Induced osteoblast differentiation by amide derivatives of stilbene: The possible osteogenic agents
- On model selections for repeated measurement data in clinical studies
- Regulation of GLUT transporters by flavonoids in androgen-sensitive and -insensitive prostate cancer cells
- Region-specific microRNA signatures in the human epididymis
- Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety
- In Vitro characterization of the endocrine disrupting effects of per- and poly-fluoroalkyl substances (PFASs) on the human androgen receptor
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.